Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Panel Abuses Purdue Over OxyContin

This article was originally published in The Pink Sheet Daily

Executive Summary

Tamper-resistant version would lead to more problems, say FDA advisors.

You may also be interested in...



Lone Wolfe: Drug Industry Critic Ends Tenure As Advisory Committee Member With Rare Decisive Vote

Sidney Wolfe’s stint as permanent member of the Drug Safety and Risk Management Advisory Committee ended May 31; his final meeting was the May 23 review of Xarelto for ACS. That gave him a second chance to vote against the product. A look back at Wolfe’s tenure shows he was a sure “no” vote when he sat on a panel—but that his service can hardly be construed as having damaged the industry.

FDA Advisors Question Impact of OxyContin Improvements Due To Generics

Purdue Pharma may be navigating a complicated regulatory path to extending its dominant market position for OxyContin

FDA Advisors Question Impact of OxyContin Improvements Due To Generics

Purdue Pharma may be navigating a complicated regulatory path to extending its dominant market position for OxyContin

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS067851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel